Preferences help
enabled [disable] Abstract
Number of results
2006 | 53 | 1 | 189-198
Article title

Altered mouse leukemia L1210 thymidylate synthase, associated with cell resistance to 5-fluoro-dUrd, is not mutated but rather reflects posttranslational modification

Title variants
Languages of publication
Thymidylate synthase purified from 5-fluoro-dUrd-resistant mouse leukemia L1210 cells (TSr) was less sensitive to slow-binding inhibition by 5-fluoro-dUMP than the enzyme from the parental cells (TSp), both enzyme forms differing also in sensitivity to several other dump analogues, apparent molecular weights of monomer and dimer, and temperature dependence of the catalyzed reaction. Direct sequencing of products obtained from RT-PCR, performed on total RNA isolated from the parental and 5-fluoro-dUrd-resistant cells, proved both nucleotide sequences to be identical to the mouse thymidylate synthase coding sequence published earlier (NCBI protein database access no. NP_067263). This suggests that the altered properties of TSr are caused by a factor different than protein mutation, presumably posttranslational modification. As a possibility of rat thymidylate synthase phosphorylation has been recently demonstrated (Samsonoff et al. (1997) J Biol Chem 272: 13281), the mouse enzyme amino-acid sequence was analysed, revealing several potential phosphorylation sites. In order to test possible influence of the protein phosphorylation state on enzymatic properties, endogenous TSp and TSr were purified in the presence of inhibitors of phosphatases. Although both enzyme forms were phosphorylated, as shown by electrophoretical separation followed by phosphoprotein detection, the extent of phosphorylation was apparently similar. However, the same two purified enzyme preparations, compared to the corresponding preparations purified in the absence of phosphatase inhibitors, showed certain properties, including sensitivity to the slow-binding inhibition by FdUMP, altered. Thus properties dependence on phosphorylation was indicated.
Physical description
  • Aschele C, Lonardi S, Monfardini S (2002) Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28: 27-47.
  • Bapat AR, Zarow C, Danenberg PV (1983) Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem 258: 4130-4136.
  • Barbour KW, Hoganson DK, Berger SH, Berger FG (1992) A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells. Mol Pharmacol 42: 242-248.
  • Berger SH, Jenh CH, Johnson LF, Berger FG (1985) Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28: 461-467.
  • Carreras CW, Santi DV (1995) The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64: 721-762.
  • Ciesla J, Weiner KX, Weiner RS, Reston JT, Maley GF, Maley F (1995) Isolation and expression of rat thymidylate synthase cDNA: phylogenetic comparison with human and mouse thymidylate synthases. Biochim Biophys Acta 1261: 233-242.
  • Ciesla J, Gołos B, Wałajtys-Rode E, Jagielska E, Płucien­niczak A, Rode W (2002) The effect of Arg 209 to Lys mutation in mouse thymidylate synthase. Acta Biochim Polon 49: 651-658.
  • Dabrowska M, Zielinski Z, Wranicz M, Michalski R, Pawełczak K, Rode W (1996) Trichinella spiralis thymidylate synthase: developmental pattern, isolation, molecular properties, and inhibition by substrate and cofactor analogues. Biochem Biophys Res Commun 228: 440-445.
  • Dabrowska M, Jagielska E, Ciesla J, Płucienniczak A, Kwiatowski J, Wranicz M, Boireau P, Rode W (2004) Trichinella spiralis thymidylate synthase: cDNA cloning and sequencing, and developmental pattern of mRNA expression. Parasitology 128: 209-221.
  • Danenberg PV, Malli H, Swenson S (1999) Thymidylate synthase inhibitors. Semin Oncol 26: 621-631.
  • Deng TL, Li DW, Jenh CH, Johnson LF (1986) Structure of the gene for mouse thymidylate synthase. Locations of introns and multiple transcriptional start sites. J Biol Chem 261: 16000-16005.
  • Douglas KT (1987) The thymidylate synthesis cycle and anticancer drugs. Med Res Rev 7: 441-475. Erratum: Med Res Rev (1989) 9: following 265.
  • Dzik JM, Zielinski Z, Ciesla J, Bretner M, Kulikowski T, Shugar D, Bertino JR, Rode W (1993) Interaction of 2-thio-5-fluoro-dUMP and 4-thio-5-fluoro-dUMP with mammalian normal and tumour, and helminthic, thymidylate synthases: influence of C(4)-substituents on specificity for enzyme inactivation. Biochem Biophys Res Commun 195: 1301-1308.
  • Fernandes DJ, Cranford SK (1985) Resistance of CCRF-CEM cloned sublines to 5-fluorodeoxyuridine associated with enhanced phosphatase activities. Biochem Pharmacol 34: 125-132.
  • Gołos B, Wałajtys-Rode E, Porebska A, Ciesla J, Dabrowska M, Zielinski Z, Rode W (2002) Thymidylate synthase heterogeneity assessed by monoclonal M antibodies. In Chemistry and Biology of Pteridines and Folates 2001 (Milstien S, Kapatos G, Levine RA, Shane B, eds) pp 519-523, Kluwer Academic Publishers, Boston.
  • Heidelberger C, Kaldor G, Mukherjee KL, Danneberg PB (1960) Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance. Cancer Res 20: 903-909.
  • Hughey CT, Barbour KW, Berger FG, Berger SH (1993) Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. Mol Pharmacol 44: 316-323.
  • Jackman AL, Jones TR, Calvert AH (1985) Thymidylate synthetase inhibitors: experimental and clinical aspects. In Experimental and Clinical Progress in Cancer Chemotherapy (Muggia FM, ed) pp 155-210, Martinus Nijhoff Publishers, Boston.
  • Jastreboff MM, Kedzierska B, Rode W (1983) Altered thymidylate synthetase in 5-fluorodeoxyuridine-resistant Ehrlich ascites carcinoma cells. Biochem Pharmacol 32: 2259-2267.
  • Kawate H, Landis DM, Loeb LA (2002) Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine. J Biol Chem 277: 36304-36311.
  • Kessel D, Wodinsky I (1970) Thymidine kinase as a determinant of the response to 5-fluoro-2'-deoxyuridine in transplantable murine leukemias. Mol Pharmacol 6: 251-254.
  • Kitchens ME, Forsthoefel AM, Barbour KW, Spencer HT, Berger FG (1999) Mechanisms of acquired resistance to thymidylate synthase inhibitors: the role of enzyme stability. Mol Pharmacol 56: 1063-1070.
  • Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
  • Lehman NL (2002) Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 11: 1775-1787.
  • Libra M, Navolanic PM, Talamini R, Cecchin E, Sartor F, Tumolo S, Masier S, Travali S, Boiocchi M, Toffoli G (2004) Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 4: 11.
  • Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ (2004) Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine. World J Gastroenterol 10: 172-176.
  • Mulkins MA, Heidelberger C (1982) Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 42: 965-973.
  • Napier MP, Ledermann JA (2000) Novel chemotherapeutic agents in colorectal cancer. Eur J Surg Oncol 26: 605-610.
  • Perryman SM, Rossana C, Deng TL, Vanin EF, Johnson LF (1986) Sequence of a cDNA for mouse thymidylate synthase reveals striking similarity with the prokaryotic enzyme. Mol Biol Evol 3: 313-321.
  • Rode W, Les A (1996) Molecular mechanism of thymidylate synthase-catalyzed reaction and interaction of the enzyme with 2- and/or 4-substituted analogues of dUMP and 5-fluoro-dUMP. Acta Biochim Polon 43: 133-142.
  • Rode W, Scanlon KJ, Hynes J, Bertino JR (1979) Purification of mammalian tumor (L1210) thymidylate synthetase by affinity chromatography on stable biospecific adsorbent. Stabilization of the enzyme with neutral detergents. J Biol Chem 254: 11538-11543.
  • Rode W, Kulikowski T, Kedzierska B, Jastreboff M, Shugar D (1984) Inhibition of mammalian tumour thymidylate synthetase by 5-alkylated 2'-deoxyuridine 5'-phosphates. Biochem Pharmacol 33: 2699-2705.
  • Rode W, Ciesla J, Zielinski Z, Kedzierska B (1986) Purification and properties of mouse thymus thymidylate synthase. Comparison of the enzyme from mammalian normal and tumour tissues. Int J Biochem 18: 361-368.
  • Rode W, Kulikowski T, Kedzierska B, Shugar D (1987) Studies on the interaction with thymidylate synthase of analogues of 2'-deoxyuridine-5'-phosphate and 5-fluoro-2'-deoxyuridine-5'-phosphate with modified phosphate groups. Biochem Pharmacol 36: 203-210.
  • Rode W, Zielinski Z, Dzik JM, Kulikowski T, Bretner M, Kierdaszuk B, Ciesla J, Shugar D (1990) Mechanism of inhibition of mammalian tumour and other thymidylate synthases by N4-hydroxy-dCMP, N4-hydroxy-5-fluoro-dCMP and related analogues. Biochemistry 29: 10835-10842.
  • Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning. A Laboratory Manual 2nd edn. Cold Spring Harbor Laboratory Press.
  • Samsonoff WA, Reston J, McKee M, O'Connor B, Galivan J, Maley GF, Maley F (1997) Intracellular location of thymidylate synthase and its state of phosphorylation. J Biol Chem 272: 13281-13285.
  • Weber K, Osborn M (1969) The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis J Biol Chem 244: 4406-4412.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.